| pubmed-article:21674534 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21674534 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:21674534 | lifeskim:mentions | umls-concept:C0013264 | lld:lifeskim |
| pubmed-article:21674534 | lifeskim:mentions | umls-concept:C0302908 | lld:lifeskim |
| pubmed-article:21674534 | lifeskim:mentions | umls-concept:C0030899 | lld:lifeskim |
| pubmed-article:21674534 | lifeskim:mentions | umls-concept:C0205169 | lld:lifeskim |
| pubmed-article:21674534 | lifeskim:mentions | umls-concept:C0524527 | lld:lifeskim |
| pubmed-article:21674534 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:21674534 | pubmed:dateCreated | 2011-7-14 | lld:pubmed |
| pubmed-article:21674534 | pubmed:abstractText | In this study we performed an open-label, pilot study of an orally administered liquid formulation of immediate-release pentoxifylline (PTX) on patients with Duchenne muscular dystrophy (DMD). Treatment efficacy, safety, and tolerability were assessed. | lld:pubmed |
| pubmed-article:21674534 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21674534 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21674534 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21674534 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21674534 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21674534 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21674534 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21674534 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21674534 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21674534 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:21674534 | pubmed:issn | 1097-4598 | lld:pubmed |
| pubmed-article:21674534 | pubmed:author | pubmed-author:ClemensPaula... | lld:pubmed |
| pubmed-article:21674534 | pubmed:author | pubmed-author:IannacconeSus... | lld:pubmed |
| pubmed-article:21674534 | pubmed:author | pubmed-author:EscolarDiana... | lld:pubmed |
| pubmed-article:21674534 | pubmed:author | pubmed-author:ZimmermanAnge... | lld:pubmed |
| pubmed-article:21674534 | pubmed:author | pubmed-author:HenricsonErik... | lld:pubmed |
| pubmed-article:21674534 | pubmed:author | pubmed-author:MayhewJillJ | lld:pubmed |
| pubmed-article:21674534 | pubmed:author | pubmed-author:Tesi-RochaCar... | lld:pubmed |
| pubmed-article:21674534 | pubmed:author | pubmed-author:ConnollyAnneA | lld:pubmed |
| pubmed-article:21674534 | pubmed:author | pubmed-author:HuFengmingF | lld:pubmed |
| pubmed-article:21674534 | pubmed:author | pubmed-author:KuntzNancyN | lld:pubmed |
| pubmed-article:21674534 | pubmed:author | pubmed-author:ArrietaAdrien... | lld:pubmed |
| pubmed-article:21674534 | pubmed:author | pubmed-author:HacheLaurenL | lld:pubmed |
| pubmed-article:21674534 | pubmed:copyrightInfo | Copyright © 2011 Wiley Periodicals, Inc. | lld:pubmed |
| pubmed-article:21674534 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21674534 | pubmed:volume | 44 | lld:pubmed |
| pubmed-article:21674534 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21674534 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21674534 | pubmed:pagination | 170-3 | lld:pubmed |
| pubmed-article:21674534 | pubmed:meshHeading | pubmed-meshheading:21674534... | lld:pubmed |
| pubmed-article:21674534 | pubmed:meshHeading | pubmed-meshheading:21674534... | lld:pubmed |
| pubmed-article:21674534 | pubmed:meshHeading | pubmed-meshheading:21674534... | lld:pubmed |
| pubmed-article:21674534 | pubmed:meshHeading | pubmed-meshheading:21674534... | lld:pubmed |
| pubmed-article:21674534 | pubmed:meshHeading | pubmed-meshheading:21674534... | lld:pubmed |
| pubmed-article:21674534 | pubmed:meshHeading | pubmed-meshheading:21674534... | lld:pubmed |
| pubmed-article:21674534 | pubmed:meshHeading | pubmed-meshheading:21674534... | lld:pubmed |
| pubmed-article:21674534 | pubmed:meshHeading | pubmed-meshheading:21674534... | lld:pubmed |
| pubmed-article:21674534 | pubmed:meshHeading | pubmed-meshheading:21674534... | lld:pubmed |
| pubmed-article:21674534 | pubmed:meshHeading | pubmed-meshheading:21674534... | lld:pubmed |
| pubmed-article:21674534 | pubmed:meshHeading | pubmed-meshheading:21674534... | lld:pubmed |
| pubmed-article:21674534 | pubmed:meshHeading | pubmed-meshheading:21674534... | lld:pubmed |
| pubmed-article:21674534 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21674534 | pubmed:articleTitle | Liquid formulation of pentoxifylline is a poorly tolerated treatment for duchenne dystrophy. | lld:pubmed |
| pubmed-article:21674534 | pubmed:affiliation | Children's National Medical Center, Washington, DC, USA. | lld:pubmed |
| pubmed-article:21674534 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21674534 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:21674534 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| pubmed-article:21674534 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:21674534 | lld:pubmed |
